B cell therapyocrelizumabofatumumabmultiple sclerosisMS
…ence of disease activity (EDA) after a minimum of six months on B cell therapy. The difference in sNfL between NEDA-3 and EDA patients was sta…
1articles mentioning treatments
3treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: B cell therapy ×
B cell therapy
This treatment is selected. Its supporting articles are shown below.